WO2003088974A1 - Pharmaceutical composition - Google Patents
Pharmaceutical composition Download PDFInfo
- Publication number
- WO2003088974A1 WO2003088974A1 PCT/US2003/012235 US0312235W WO03088974A1 WO 2003088974 A1 WO2003088974 A1 WO 2003088974A1 US 0312235 W US0312235 W US 0312235W WO 03088974 A1 WO03088974 A1 WO 03088974A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- testosterone
- composition
- patient
- composition according
- androgen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (36)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002470200A CA2470200C (en) | 2002-04-19 | 2003-04-21 | Pharmaceutical composition |
DE60315939T DE60315939T2 (en) | 2002-04-19 | 2003-04-21 | PHARMACEUTICAL COMPOSITION CONTAINING AN ANDROGEN |
BR0309390-5A BR0309390A (en) | 2002-04-19 | 2003-04-21 | Pharmaceutical Composition |
EP03726373A EP1425019B1 (en) | 2002-04-19 | 2003-04-21 | Pharmaceutical composition comprising an androgen |
EA200401410A EA009839B1 (en) | 2002-04-19 | 2003-04-21 | Pharmaceutical composition for enhancing transdermal delivery of androgen and method for use thereof |
CN038142368A CN1662243B (en) | 2002-04-19 | 2003-04-21 | Pharmaceutical composition |
US10/473,724 US7320968B2 (en) | 2002-04-19 | 2003-04-21 | Pharmaceutical composition |
AU2003228612A AU2003228612B2 (en) | 2002-04-19 | 2003-04-21 | Pharmaceutical Composition |
KR1020047016828A KR100952786B1 (en) | 2002-04-19 | 2003-04-21 | Pharmaceutical composition |
DK03726373T DK1425019T3 (en) | 2002-04-19 | 2003-04-21 | Pharmaceutical composition comprising an androgen |
NZ535970A NZ535970A (en) | 2002-04-19 | 2003-04-21 | Pharmaceutical composition comprising an androgen, a Hsieh enhancer and a thickening agent |
MXPA04010311A MXPA04010311A (en) | 2002-04-19 | 2003-04-21 | Pharmaceutical composition. |
JP2003585726A JP2005519985A (en) | 2002-04-19 | 2003-04-21 | Pharmaceutical composition |
IL164547A IL164547A (en) | 2002-04-19 | 2004-10-13 | Pharmaceutical composition comprising an androgen, a hsieh enhancer and a thickener |
IS7535A IS2667B (en) | 2002-04-19 | 2004-11-17 | An androgen-containing pharmaceutical composition |
NO20045019A NO335864B1 (en) | 2002-04-19 | 2004-11-18 | A pharmaceutical composition comprising testosterone or dihydrotestosterone and oxacyclohexadecan-2-one; use thereof for the manufacture of a medicament and process for the preparation of the composition. |
HK06102651.0A HK1082682A1 (en) | 2002-04-19 | 2006-02-28 | Pharmaceutical composition |
US11/929,610 US20080103120A1 (en) | 2002-04-19 | 2007-10-30 | Pharmaceutical composition |
US11/928,467 US7935690B2 (en) | 2002-04-19 | 2007-10-30 | Pharmaceutical composition |
US11/930,812 US8063029B2 (en) | 2002-04-19 | 2007-10-31 | Pharmaceutical composition |
US11/931,809 US8178518B2 (en) | 2002-04-19 | 2007-10-31 | Pharmaceutical composition |
US12/356,515 US7608606B2 (en) | 2002-04-19 | 2009-01-20 | Pharmaceutical composition |
US12/356,513 US7608605B2 (en) | 2002-04-19 | 2009-01-20 | Pharmaceutical composition |
US12/356,943 US7608607B2 (en) | 2002-04-19 | 2009-01-21 | Pharmaceutical composition |
US12/359,162 US7608608B2 (en) | 2002-04-19 | 2009-01-23 | Pharmaceutical composition |
US12/359,183 US7608609B2 (en) | 2002-04-19 | 2009-01-23 | Pharmaceutical composition |
US12/364,413 US7608610B2 (en) | 2002-04-19 | 2009-02-02 | Pharmaceutical composition |
US12/407,418 US20090192131A1 (en) | 2002-04-19 | 2009-03-19 | Pharmaceutical Composition |
US12/407,460 US20090192132A1 (en) | 2002-04-19 | 2009-03-19 | Pharmaceutical Composition |
US12/570,847 US20100081640A1 (en) | 2002-04-19 | 2009-09-30 | Pharmaceutical composition |
US13/444,637 US20210308145A1 (en) | 2002-04-19 | 2012-04-11 | Pharmaceutical Composition |
US13/566,633 US20210308146A1 (en) | 2002-04-19 | 2012-08-03 | Pharmaceutical composition |
US13/601,572 US20130059828A1 (en) | 2002-04-19 | 2012-08-31 | Pharmaceutical composition |
US13/921,879 US20130281416A1 (en) | 2002-04-19 | 2013-06-19 | Pharmaceutical composition |
US14/196,705 US20140343025A1 (en) | 2002-04-19 | 2014-03-04 | Pharmaceutical composition |
US14/680,197 US20150283153A1 (en) | 2002-04-19 | 2015-04-07 | Pharmaceutical composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37410302P | 2002-04-19 | 2002-04-19 | |
US60/374,103 | 2002-04-19 |
Related Child Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/473,724 A-371-Of-International US7320968B2 (en) | 2002-04-19 | 2003-04-21 | Pharmaceutical composition |
US10/473,724 Continuation US7320968B2 (en) | 2002-04-19 | 2003-04-21 | Pharmaceutical composition |
US11/929,610 Division US20080103120A1 (en) | 2002-04-19 | 2007-10-30 | Pharmaceutical composition |
US11/928,467 Continuation US7935690B2 (en) | 2002-04-19 | 2007-10-30 | Pharmaceutical composition |
US11/931,809 Continuation US8178518B2 (en) | 2002-04-19 | 2007-10-31 | Pharmaceutical composition |
US11/930,812 Continuation US8063029B2 (en) | 2002-04-19 | 2007-10-31 | Pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003088974A1 true WO2003088974A1 (en) | 2003-10-30 |
Family
ID=29251138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/012235 WO2003088974A1 (en) | 2002-04-19 | 2003-04-21 | Pharmaceutical composition |
Country Status (30)
Country | Link |
---|---|
US (21) | US7320968B2 (en) |
EP (2) | EP1425019B1 (en) |
JP (1) | JP2005519985A (en) |
KR (2) | KR100977896B1 (en) |
CN (2) | CN1662243B (en) |
AR (2) | AR039644A1 (en) |
AT (1) | ATE371456T1 (en) |
AU (1) | AU2003228612B2 (en) |
BR (1) | BR0309390A (en) |
CA (1) | CA2470200C (en) |
CY (1) | CY1109005T1 (en) |
DE (1) | DE60315939T2 (en) |
DK (1) | DK1425019T3 (en) |
EA (1) | EA009839B1 (en) |
EG (1) | EG24882A (en) |
ES (2) | ES2399900T3 (en) |
HK (3) | HK1082682A1 (en) |
IL (1) | IL164547A (en) |
IS (2) | IS2667B (en) |
LT (1) | LT5235B (en) |
LV (1) | LV13303B (en) |
MX (1) | MXPA04010311A (en) |
MY (1) | MY139721A (en) |
NO (1) | NO335864B1 (en) |
NZ (1) | NZ535970A (en) |
PL (1) | PL213976B1 (en) |
SA (1) | SA03240158B1 (en) |
TW (1) | TWI362932B (en) |
WO (1) | WO2003088974A1 (en) |
ZA (1) | ZA200408422B (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004110398A1 (en) * | 2003-06-06 | 2004-12-23 | Besins International Belgique | Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof |
EP1634583A1 (en) * | 2004-09-09 | 2006-03-15 | Laboratoires Besins International | Testosterone gels comprising propylene glycol as penetration enhancer |
JP2008512425A (en) * | 2004-09-09 | 2008-04-24 | ラボラトワール ブザン アンテルナスィヨナル | Testosterone gel with propylene glycol as a penetration enhancer |
JP2008534644A (en) * | 2005-04-08 | 2008-08-28 | ラボラトワール ベジン アンテルナスィオナル | Method for treating or preventing type 2 diabetes |
EP2640397A1 (en) * | 2010-11-18 | 2013-09-25 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
US9125816B2 (en) | 2000-08-30 | 2015-09-08 | Besins Healthcare Inc. | Pharmaceutical composition and method for treating hypogonadism |
US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
US10111888B2 (en) | 2011-05-13 | 2018-10-30 | Acerus Biopharma Inc. | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
WO2019089942A1 (en) * | 2017-11-02 | 2019-05-09 | Rick Coulon | Formulations for use in the transdermal delivery of proteasome inhibitors |
US10668084B2 (en) | 2011-05-13 | 2020-06-02 | Acerus Biopharma Inc. | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
EP2714006B1 (en) * | 2011-05-15 | 2020-12-09 | Acerus Biopharma Inc. | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism |
US11090312B2 (en) | 2013-03-15 | 2021-08-17 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
US20030139384A1 (en) * | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
MY139721A (en) | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
US20040259852A1 (en) * | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
AU2006299833B2 (en) | 2005-10-12 | 2012-04-12 | Besins Healthcare Luxembourg Sarl | Improved testosterone gel and method of use |
CN102088956A (en) * | 2008-05-09 | 2011-06-08 | 托马有限公司 | Proguanil to treat skin/mucosal diseases |
JP2011522830A (en) * | 2008-06-05 | 2011-08-04 | シーペックス ファーマシューティカルズ、インク. | Insulin preparation for insulin |
US20110097363A1 (en) * | 2009-10-22 | 2011-04-28 | Cpex Pharmaceuticals, Inc. | Therapeutically Effective Preparations of Insulin |
EP2640398A4 (en) | 2010-11-18 | 2014-05-14 | White Mountain Pharma Inc | Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein |
US10568905B2 (en) * | 2012-02-14 | 2020-02-25 | Metabolic Therapy Inc. | Pharmaceutical composition and method for treating retinal neurodegeneration |
EP2833944A4 (en) | 2012-04-06 | 2016-05-25 | Antares Pharma Inc | Needle assisted jet injection administration of testosterone compositions |
CA2885142A1 (en) | 2012-09-20 | 2014-03-27 | Leonard Austin Hensel | Lock ring spreader |
US8785426B1 (en) | 2013-12-13 | 2014-07-22 | Upsher-Smith Laboratories, Inc. | Testosterone gel compositions and related methods |
US20170014417A1 (en) | 2015-07-14 | 2017-01-19 | Lipp Life Sciences Llc | Pharmaceutical administration system for the transdermal application of vardenafil |
CN112666197B (en) * | 2020-11-29 | 2022-11-04 | 山东大学 | Rock slag quartz content testing system and method for TBM |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968919A (en) * | 1997-10-16 | 1999-10-19 | Macrochem Corporation | Hormone replacement therapy drug formulations for topical application to the skin |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3989815A (en) * | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Novel N-bis-azacyclopentan-2-onyl alkanes |
US4316893A (en) * | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
US4405616A (en) * | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
US3989816A (en) * | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
BE843140A (en) * | 1975-06-19 | 1976-10-18 | AAZACYCLOALCAN-2-ONES 1-SUBSTITUTES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AS EXCIPIENTS | |
US3991203A (en) * | 1975-06-19 | 1976-11-09 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
US4424210A (en) * | 1980-04-04 | 1984-01-03 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
US4444762A (en) * | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
US4423040A (en) * | 1980-04-04 | 1983-12-27 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclohexan-2-ones |
US4415563A (en) * | 1980-04-04 | 1983-11-15 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclononan-2-ones |
US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5731303A (en) | 1985-12-04 | 1998-03-24 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery compositions |
US4992422A (en) * | 1986-01-31 | 1991-02-12 | Whitby Research, Inc. | Compositions comprising 1-substituted azacycloalkanes |
US5270346A (en) | 1986-01-31 | 1993-12-14 | Whitby Research, Inc. | Penetration enhancers for transdermal delivery of systemic agents |
US4801586A (en) | 1986-04-23 | 1989-01-31 | Nelson Research & Development Co. | Penetration enhancers for transdermal delivery of systemic agents |
US4879275A (en) | 1987-09-30 | 1989-11-07 | Nelson Research & Development Co. | Penetration enhancers for transdermal delivery of systemic agent |
US5019395A (en) | 1988-03-08 | 1991-05-28 | Warner-Lambert Company | Compositions with enhanced penetration |
US5676968A (en) * | 1991-10-31 | 1997-10-14 | Schering Aktiengesellschaft | Transdermal therapeutic systems with crystallization inhibitors |
US6190691B1 (en) * | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
DE19619045C1 (en) | 1996-05-02 | 1997-11-13 | Jenapharm Gmbh | Use of combination products for the treatment of hypogonadal men and men with pituitary disorders |
US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US6019997A (en) * | 1997-01-09 | 2000-02-01 | Minnesota Mining And Manufacturing | Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents |
DE19701949A1 (en) | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermal therapeutic system |
KR20040004416A (en) * | 1997-01-30 | 2004-01-13 | 노파르티스 아게 | Oil-Free Pharmaceutical Compositions Containing Cyclosporin A |
DE19709960A1 (en) * | 1997-03-11 | 1998-09-24 | Aesculap Ag & Co Kg | Method and device for preoperatively determining the position data of endoprosthesis parts |
JP4139860B2 (en) * | 1997-11-10 | 2008-08-27 | ストラカン インターナショナル リミティッド | Penetration enhancement and stimulation reduction system |
US6980952B1 (en) * | 1998-08-15 | 2005-12-27 | Texas Instruments Incorporated | Source normalization training for HMM modeling of speech |
EP1031564A1 (en) * | 1999-02-26 | 2000-08-30 | Klinge Pharma GmbH | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy |
FR2801507B1 (en) * | 1999-11-30 | 2003-06-27 | Pf Medicament | SELF-ADHESIVE TRANSDERMAL DEVICE COMPRISING A RESERVOIR AND A MATRIX CONTAINING THE SAME ACTIVE INGREDIENT, ITS PREPARATION METHOD AND ITS USES |
SK12682001A3 (en) * | 1999-12-08 | 2002-07-02 | Pharmacia Corporation, Corporate Patent Department | Solid-state form of celecoxib having enhanced bioavailability |
US6495124B1 (en) | 2000-02-14 | 2002-12-17 | Macrochem Corporation | Antifungal nail lacquer and method using same |
US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
US7214381B2 (en) * | 2000-08-03 | 2007-05-08 | Antares Pharma Ipl Ag | Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
EP2283865A1 (en) | 2000-08-30 | 2011-02-16 | Unimed Pharmaceuticals, LLC | Method of increasing testosterone and related steroid concentrations in women |
US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
MXPA03001859A (en) * | 2000-08-30 | 2004-05-21 | Unimed Pharmaceuticals Inc | Method of increasing testosterone and related steroid concentrations in women. |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US20030139384A1 (en) * | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
WO2002055020A2 (en) | 2000-12-11 | 2002-07-18 | Testocreme Llc | Topical testosterone formulations and associated methods |
DE20121209U1 (en) * | 2000-12-22 | 2002-06-20 | August Wolff Gmbh & Co Arzneim | Gel composition for the treatment of hypogonadism |
WO2002089849A1 (en) * | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
US20030027804A1 (en) | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
US7169107B2 (en) * | 2002-01-25 | 2007-01-30 | Karen Jersey-Willuhn | Conductivity reconstruction based on inverse finite element measurements in a tissue monitoring system |
EP1511494B1 (en) | 2002-03-15 | 2020-08-19 | Unimed Pharmaceuticals, LLC | Androgen pharmaceutical composition and method for treating depression |
MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
US20040259784A1 (en) * | 2003-06-18 | 2004-12-23 | White Hillary D. | Compositions and methods for treatment of muscle pain and muscle wasting |
-
2003
- 2003-04-18 MY MYPI20031462A patent/MY139721A/en unknown
- 2003-04-19 EG EG2003040351A patent/EG24882A/en active
- 2003-04-21 AT AT03726373T patent/ATE371456T1/en active
- 2003-04-21 EP EP03726373A patent/EP1425019B1/en not_active Expired - Lifetime
- 2003-04-21 CA CA002470200A patent/CA2470200C/en not_active Expired - Fee Related
- 2003-04-21 CN CN038142368A patent/CN1662243B/en not_active Expired - Fee Related
- 2003-04-21 AR ARP030101362A patent/AR039644A1/en not_active Application Discontinuation
- 2003-04-21 KR KR1020097013431A patent/KR100977896B1/en not_active IP Right Cessation
- 2003-04-21 BR BR0309390-5A patent/BR0309390A/en not_active IP Right Cessation
- 2003-04-21 ES ES06018822T patent/ES2399900T3/en not_active Expired - Lifetime
- 2003-04-21 ES ES03726373T patent/ES2292964T3/en not_active Expired - Lifetime
- 2003-04-21 JP JP2003585726A patent/JP2005519985A/en active Pending
- 2003-04-21 DE DE60315939T patent/DE60315939T2/en not_active Expired - Lifetime
- 2003-04-21 NZ NZ535970A patent/NZ535970A/en not_active IP Right Cessation
- 2003-04-21 MX MXPA04010311A patent/MXPA04010311A/en active IP Right Grant
- 2003-04-21 DK DK03726373T patent/DK1425019T3/en active
- 2003-04-21 AU AU2003228612A patent/AU2003228612B2/en not_active Ceased
- 2003-04-21 WO PCT/US2003/012235 patent/WO2003088974A1/en active IP Right Grant
- 2003-04-21 EA EA200401410A patent/EA009839B1/en not_active IP Right Cessation
- 2003-04-21 US US10/473,724 patent/US7320968B2/en active Active - Reinstated
- 2003-04-21 EP EP06018822A patent/EP1741433B1/en not_active Expired - Lifetime
- 2003-04-21 TW TW092109215A patent/TWI362932B/en not_active IP Right Cessation
- 2003-04-21 PL PL372083A patent/PL213976B1/en unknown
- 2003-04-21 KR KR1020047016828A patent/KR100952786B1/en not_active IP Right Cessation
- 2003-04-21 CN CN201110259341.7A patent/CN102357098B/en not_active Expired - Fee Related
- 2003-06-22 SA SA03240158A patent/SA03240158B1/en unknown
-
2004
- 2004-10-13 IL IL164547A patent/IL164547A/en not_active IP Right Cessation
- 2004-10-18 ZA ZA200408422A patent/ZA200408422B/en unknown
- 2004-10-27 LV LVP-04-127A patent/LV13303B/en unknown
- 2004-11-17 IS IS7535A patent/IS2667B/en unknown
- 2004-11-18 NO NO20045019A patent/NO335864B1/en not_active IP Right Cessation
- 2004-11-18 LT LT2004101A patent/LT5235B/en not_active IP Right Cessation
-
2006
- 2006-02-28 HK HK06102651.0A patent/HK1082682A1/en not_active IP Right Cessation
-
2007
- 2007-05-25 HK HK07105491.6A patent/HK1098386A1/en not_active IP Right Cessation
- 2007-10-30 US US11/928,467 patent/US7935690B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/929,610 patent/US20080103120A1/en not_active Abandoned
- 2007-10-31 US US11/931,809 patent/US8178518B2/en not_active Expired - Lifetime
- 2007-10-31 US US11/930,812 patent/US8063029B2/en not_active Expired - Fee Related
- 2007-11-26 CY CY20071101504T patent/CY1109005T1/en unknown
-
2009
- 2009-01-20 US US12/356,513 patent/US7608605B2/en not_active Expired - Fee Related
- 2009-01-20 US US12/356,515 patent/US7608606B2/en not_active Expired - Fee Related
- 2009-01-21 US US12/356,943 patent/US7608607B2/en not_active Expired - Fee Related
- 2009-01-23 US US12/359,162 patent/US7608608B2/en not_active Expired - Fee Related
- 2009-01-23 US US12/359,183 patent/US7608609B2/en not_active Expired - Fee Related
- 2009-02-02 US US12/364,413 patent/US7608610B2/en not_active Expired - Fee Related
- 2009-03-19 US US12/407,418 patent/US20090192131A1/en not_active Abandoned
- 2009-03-19 US US12/407,460 patent/US20090192132A1/en not_active Abandoned
- 2009-09-30 US US12/570,847 patent/US20100081640A1/en not_active Abandoned
-
2010
- 2010-01-06 IS IS8870A patent/IS2946B/en unknown
-
2012
- 2012-04-11 US US13/444,637 patent/US20210308145A1/en not_active Abandoned
- 2012-08-03 US US13/566,633 patent/US20210308146A1/en not_active Abandoned
- 2012-08-08 AR ARP120102894A patent/AR087484A2/en unknown
- 2012-08-16 HK HK12108063.1A patent/HK1167332A1/en not_active IP Right Cessation
- 2012-08-31 US US13/601,572 patent/US20130059828A1/en not_active Abandoned
-
2013
- 2013-06-19 US US13/921,879 patent/US20130281416A1/en not_active Abandoned
-
2014
- 2014-03-04 US US14/196,705 patent/US20140343025A1/en not_active Abandoned
-
2015
- 2015-04-07 US US14/680,197 patent/US20150283153A1/en not_active Abandoned
-
2016
- 2016-01-19 US US15/000,848 patent/US20160129016A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968919A (en) * | 1997-10-16 | 1999-10-19 | Macrochem Corporation | Hormone replacement therapy drug formulations for topical application to the skin |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9125816B2 (en) | 2000-08-30 | 2015-09-08 | Besins Healthcare Inc. | Pharmaceutical composition and method for treating hypogonadism |
US9132089B2 (en) | 2000-08-30 | 2015-09-15 | Besins Healthcare Inc. | Pharmaceutical composition and method for treating hypogonadism |
WO2004110398A1 (en) * | 2003-06-06 | 2004-12-23 | Besins International Belgique | Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof |
EP1634583A1 (en) * | 2004-09-09 | 2006-03-15 | Laboratoires Besins International | Testosterone gels comprising propylene glycol as penetration enhancer |
WO2006027278A1 (en) | 2004-09-09 | 2006-03-16 | Laboratoires Besins International | Testosterone gels comprising propylene glycol as penetration enhancer |
JP2008512425A (en) * | 2004-09-09 | 2008-04-24 | ラボラトワール ブザン アンテルナスィヨナル | Testosterone gel with propylene glycol as a penetration enhancer |
EA013430B1 (en) * | 2004-09-09 | 2010-04-30 | Лаборатуар Безен Энтернасьональ | Testosterone gels comprising propylene glycol as penetration enhancer |
EP2957279A1 (en) * | 2004-09-09 | 2015-12-23 | Besins Healthcare Luxembourg SARL | Testosterone gels comprising propylene glycol as penetration enhancer |
JP2008534644A (en) * | 2005-04-08 | 2008-08-28 | ラボラトワール ベジン アンテルナスィオナル | Method for treating or preventing type 2 diabetes |
EP2640397A4 (en) * | 2010-11-18 | 2014-05-07 | White Mountain Pharma Inc | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
EP2640397A1 (en) * | 2010-11-18 | 2013-09-25 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
US10111888B2 (en) | 2011-05-13 | 2018-10-30 | Acerus Biopharma Inc. | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US10668084B2 (en) | 2011-05-13 | 2020-06-02 | Acerus Biopharma Inc. | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
EP2714006B1 (en) * | 2011-05-15 | 2020-12-09 | Acerus Biopharma Inc. | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism |
US11090312B2 (en) | 2013-03-15 | 2021-08-17 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
WO2019089942A1 (en) * | 2017-11-02 | 2019-05-09 | Rick Coulon | Formulations for use in the transdermal delivery of proteasome inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7608606B2 (en) | Pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 10473724 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003585726 Country of ref document: JP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003726373 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2003726373 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2470200 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2323/CHENP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 535970 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/08422 Country of ref document: ZA Ref document number: 372083 Country of ref document: PL Ref document number: 200408422 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047016828 Country of ref document: KR Ref document number: PA/A/2004/010311 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003228612 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004 20040127 Country of ref document: LV Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004101 Country of ref document: LT Ref document number: 1200401215 Country of ref document: VN Ref document number: 200401410 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2004-501645 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038142368 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047016828 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004101 Country of ref document: LT |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004101 Country of ref document: LT |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003726373 Country of ref document: EP |